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Inhibition of Pancreaticobiliary Secretion by Loperamide in Humans
P a u l W . L. T h im ist e r ,1 W im P. M. H o p m a n ,1 Ro l f F. C. v a n Ro e r m u n d ,1 H ans L. W illem s,2 G erd Rosenbusch, R o b er t W o e s t e n b o r g h s 4 a n d J a n B. M . J. J a n s e n 1
Loperamide, a peripherally acting opiate receptor agonist with antidiarrheal action, inhibits ileal and colonic motor function. It was determined whether loperamide also affects gallbladder emptying and pancreatic enzyme secretion in hu mans. Plasma cholecystokinin (radioimmunoassay), gallblad der volume (ultrasonography), and intraduodenal bilirubin and amylase output (spot sampling) were measured at regular intervals before and during intraduodenal perfusion of an amino acid meal in 8 healthy subjects: once without and once with pretreatment of 8 mg loperamide, ingested 13 and 4 hours before the start of the meal. Loperamide decreased basal amylase output from 3.2 ± 0.5 to 1.0 ± 0.5 kU/h (P < ,005) and abolished basal bilirubin output (21 ± 5 vs. 0 ± 0 ¿¿mol/h; P < .005) into the duodenum. Loperamide increased basal gallbladder volume from 28 ± 4 to 39 ± 4 mL (P < .0001) but was without effect on basal plasma cholecystokinin (2.7 ± 0.3 vs. 3.0 ± 0.3 pmol/L). During the amino acid meal, pretreatment w ith loperamide inhibited amylase output from 5.1 ± 0.8 to 1.6 ± 0.4 kU/h (P < .001), bilirubin output from 39 ± 6 to 18 ± 6 ¿¿mol/h (P < .0005) and gallbladder contraction from 47% ± 3% to 26% ± 6% (P < .05), whereas loperamide enhanced amino acid-stim ulated plasma cholecystokinin from 4.5 ± 1.6 to 7.6 ± 1.0 pmol/L (P < .05). It is concluded that loperamide inhibits basal and amino acid-stim ulated gallbladder motility and intraduodenal output of bilirubin and amylase, despite an enhanced postprandial cholecystokinin release. (H e p a t o lo g y 1997; 26:256-261.) Loperamide is widely used for the treatment of patients with diarrhea resulting from a variety of diseases.1,2 Dosages used to treat acute or chronic diarrhea vary from 2 to 16 mg daily.1 Recently, even higher dosages have been recommended. Loperamide probably exerts its antidiarrheal action by a change in motor function of the intestine, resulting in an increased capacitance of the gut and a delay in the passage of fluid through the intestine.1,3 Some studies also suggest antisecretory effects of the drug at the intestinal level.4,5 The effects of loperamide on pancreaticobiliary functions are poorly investigated. Inhibition of gallbladder emptying or pancreatic enzyme secretion by loperamide may have im portant clinical implications because stasis of bile is a major factor contributing to the formation of gallstones6'10 and be cause impairment of pancreatic enzyme secretion may induce or aggravate maldigestion. [11] [12] [13] The aim of this study, therefore, was to determine the effect of loperamide on basal and meal-stimulated gallbladder motility and pancreatic enzyme secretion in healthy volun teers. Gallbladder emptying and pancreatic enzyme secretion were studied in response to an intraduodenal amino acid meal to circumvent possible influences of loperamide on gas tric emptying or on the digestion of nutrients.14
PATIENTS AND METHODS
Subjects. Eight healthy volunteers (3 w om en and 5 men; age range, 19-27 years) participated in the studies. None of the volun teers was taking any m edication or had a history of gastrointestinal sym ptom s or surgery. The study protocol was approved by the ethical com m ittee of the University H ospital Nijmegen, and all sub jects gave their written inform ed consent before entering the study.
Reagents. Loperamide chloride was obtained from Janssen Phar m aceutica (Beerse, Belgium). Radioiodinated porcine pancreatic polypeptide was obtained from Novo N ordisk AS (Bagsvaerd, Den m ark). Synthetic CCK33 was from Peninsula Laboratories Europe, S itu iy P rotocol After a 12-hour fast, the volunteers presented at the laboratory at 7:30 am. In random order, two experiments were perform ed separated from each other by at least 1 week. At the beginning of each test a double-lum en polyvinyl tube with an OD of 5.7 m m was placed in the duodenum . The proximal lum en of the tube was positioned at the level of the papilla Vateri, and the distal lum en was positioned at the ligam ent of Treitz. The position of the tube was verified by fluoroscopy. In addition, an in-dwelling intravenous catheter was placed in a forearm. The catheter was kept p atent by a heparine-saline solution and was used for the collection of blood samples. After an equilibration period of at least 30 m in utes, the following tests were perform ed. In test 1, saline (300 mosmol/L) was continuously perfused intraduodenally for 2 hours (300 m L/h) together with the recovery m arker PEG-4000 (6g/L). D uring the third test hour, an isoosm otic solution (300 mOsm; F ig . 1. Study protocol for the two tests performed in random order. In both tests, saline was continuously perfused intraduodenally together with the recovery marker PEG-4000 (1,8 g/li) from -60 to 120 minutes at a constant rate of 5 mL/h. During the last test hour, 6.89 g of an amino acid solution was also perfused intraduodenally. In one of the two tests* loperamide (8 mg) was ingested 13 and 4 hours before the start of the amino acid perfusion. *Time points when blood was drawn for the measurement of plasma CCK and pancreatic polypeptide levels, whereas gallbladder volume was determined by ultrasonography. +Time points when duodenal juice was sampled for the determination of bilirubin and amylase. mL) and dem ineralized w ater (160 mL). Test 2 was perform ed according to the same protocol as test 1. However, 13 and 4 h o u rs before the start of the amino acid perfusion, 8 m g of loperam ide was administered orally ( Fig. 1 ). Five-milliliter samples of d u o d en al contents were taken during 15-m inute periods from the tip o f the tube by spot-sam pling16 and kept on ice. Blood samples w ere taken every 30 m inutes during the first hour and subsequently every 15 m inutes until the end of the test period ( Fig. 1 ).
Blood was collected into ice-chilled glass tubes containing 2 g/L of ethylenediam inetetraacetic acid. After the experim ents, the b lo o d samples were centrifuged at 4°C for 15 m inutes (3,000g). In test 2, an additional blood sam ple was taken just before the start of the amino acid perfusion for m easurem ent of plasma loperam ide levels. Plasma and duodenal samples were stored at -20°C until assayed for cholecystokinin (CCK), pancreatic polypeptide, loperam ide, PEG-4000, bilirubin, and amylase. Each time that a blood sam ple was taken, two longitudinal and two transverse images of the gall bladder were obtained by real-time ultrasonography.
Plasma Samples. Plasma CCK was measured by a sensitive an d specific radioim m unoassay as described previously.17,18 T he a n ti body used (T204) binds to biologically active CCK peptides co n taining the sulfated tyrosine region with almost equal affinity. O n a molar base, sulfated gastrins cross-reacted < 2% in the assay, whereas no cross-reactivity w ith unsulfated gastrins or structurally unrelated peptides was found. The detection limit of the assay was between 0.5 and 1.0 pmol/L CCK in plasma. The intra-assay p reci sion ranged from 4.6% to 11.5% in the steep part of the stan d ard curve. All m easurem ents of plasma CCK levels w ere perform ed in the same run.
Plasma pancreatic polypeptide levels were also determ ined by radioim m unoassay. 19 The antibody used showed no cross-reactivity with struc tur ally related gastrointestinal regulatory peptides, su ch as peptide YY or neuropeptide Y, or with structurally u n related peptides. The detection lim it of the assay was 0.5 pm ol/L of in c u b a tion mixture. The intra-assay variation ranged from 4% to 7% in the steep part of the standard curve. All m easurem ents of plasm a pancreatic polypeptide levels were performed in one run.
Plasma loperam ide levels were determ ined at the departm ent of Drug, Metabolism and Pharmacokinetics, Janssen Pharm aceutica, Beerse, Belgium, as described previously.20 1). Intraduodenal adm inistration of the amino acid meal in duced a significant (P < .05) increase of plasma pancreatic polypeptide from 25 ± 5 to 36 ± 7 pmol/L ( Fig. 3 ) and of plasma CCK from 2.7 ± 0.3 to 4.5 ± 1.6 pmol/L (Fig. 2) . Loperamide induced a statistically significant (P < ,05) en hancement of the amino acid-stim ulated plasma CCK level from 4.5 ± 1.6 to 7.6 ± 1.0 pmol/L ( Fig. 2 and Table 1 ) but inhibited (P < .05) amino acid-stim ulated plasma pancre atic polypeptide levels from 36 ± 7 to 28 ± 7 pmol/L ( Fig.  3 and Table 1 ).
Gallbladder Volume and Bilirubin Output. After pretreatment with loperamide, basal gallbladder volume was significantly greater than in the control experiment (39 ± 4 mL vs. 28 ± 4 mL; P < .0001; Fig. 4 and Table 1 ). This increase in gallbladder volume was accompanied by complete inhibition of bilirubin output into the duodenum under basal condi tions (Fig, 5 and Table 1 ). Intraduodenal perfusion of amino acids resulted in significant gallbladder contraction (P < .0001) and bilirubin output (P < .01) into the duodenum ( Fig. 4 and Table 1 ). Loperamide significantly (P < .05) attenuated maximum gallbladder contraction in response to the amino acid meal from 47% ± 3% to 26% ± 6% ( Fig. 4 and Table 1 ) and intraduodenal bilirubin output from 39 ± 6 to 18 ± 6 jumol/h (P < .0001; Fig. 5 and Table 1 ).
Pancreatic Enzyme Output. Loperamide inhibited basal amy lase output from 3.2 ± 0,5 to 1.0 ± 0.5 kU/h (P < .005) and amino acid stimulated output from 5.1 ± 0.8 to 1.6 ± 0.4 kU/h (P < .001; Fig. 6 and Table 1 ).
DISCUSSION
Loperamide is a synthetic opiate receptor agonist that se lectively interacts with peripheral opiate receptors in the di gestive tract.1,27'29 Enkephalins are natural ligands for these receptors. Enkephalins have not only been shown in the colon, where loperamide competes with these ligands to in hibit bowel movements, but also in other places of the diges tive system, such as the gastric antrum, duodenum, pancreas, cystic duct, and bile duct. 27, 30 The results of the present study (with the administration of loperamide causing plasma levels in the therapeutical range1) provide evidence that loperamide not only interacts with peripheral opiate receptors in the colon but also with opiate receptors in the proximal part of the intestinal tract, because we have found that loperamide inhibits basal and amino acid-stimulated gallbladder m otil ity an d bilirubin output, as well as amylase output.
Several studies show that ultrasonography and the sum of cylinders method is a reliable, accurate, and precise m ethod for quantification of gallbladder volume and gallbladder con traction in humans. 6,31-34 However, it has to be noted that the changes in gallbladder volume as measured by ultraso nography do not necessarily reflect the total amount of bile em ptied from the gallbladder. The gallbladder probably does not em pty in a steady progressive fashion in response to a meal, b u t filling and emptying occur more or less sim ultane ously.35"37 Jazrawi et al. provided evidence that refilling of the gallbladder starts immediately after the ingestion of a m eal an d that the total volume of bile expelled by the gall bladder postprandially amounts to up to six times its basal volum e.36 They argued that the majority of hepatic bile enters the gallbladder before reaching the duodenum even in the postprandial period. 35, 36 This indicates that the cumulative b iliru b in output into the duodenum may be a good estimate of the total amount of bile handled by the gallbladder. The data o f the present study indicate that loperamide potently in h ib ited gallbladder motor function as measured both by ultrasonography and by intraduodenal bilirubin output.
In a previous study, it was shown that loperamide inhibited basal an d meal-stimulated trypsin and bilirubin output into the duodenum of patients with a short bowel syndrom e.38 F rom that study, it was not clear whether loperamide inhib ited these functions by inhibition of gastric emptying 39 re su ltin g in a diminished supply of food to stimulating recep tors for gallbladder contraction and pancreatic enzyme secretion in the duodenum. To exclude effects of loperamide on gastric emptying, we administered the test meal into the duodenum . An elementary test meal was used to exclude possible confounding effects of loperamide on nutrient diges tion, because we have shown previously that appropriate digestion of protein is essential for stimulation of CCK re lease and pancreaticobiliary secretion in humans. 14 It h as been suggested that the inhibitory effect of the opioid peptide enkephalin on meal-stimulated pancreatic protein secretion in dogs was mediated by a reduction in the release of CCK.40,41 According to our data, the evidence in humans is otherwise because the release of CCK in response to a meal is enhanced by loperamide. A prolonged contact time between stimulating nutrients and CCK-secreting cells may be I'esponsible for this enhanced release of CCK by lopera mide because loperamide delays the passage of fluid through the intestine. In a previous study, we have shown that lopera mide inhibits gallbladder contraction in response to intrave nously administered CCK, resulting in plasma CCK concen trations as observed after a meal.42 W e therefore postulate that the sensitivity of the pancreas and gallbladder to respond to an amino acid meal (causing increases of CCK in the physiological range as observed postprandially) is attenuated by loperamide because of interference with opioid receptors on the pancreas and gallbladder. Subsequently, according to the negative feedback concept between pancreaticobiliary output and CCK release,43'46 the diminished output of pan creaticobiliary products into the duodenum enhances the release of CCK.
Recently, it was shown that enkephalin attenuates pancre atic enzyme secretion in the rat by inhibiting the release of acetylcholine.47 A direct effect of opioids on pancreatic acini was unlikely. 48 In hum ans, loperamide may also attenuate pancreaticobiliary secretion by inhibiting the release of ace tylcholine. The finding of decreased pancreatic polypeptide levels, a hormone that is primarily controlled cholinergically,49,30 after administration of loperamide supports the hy pothesis that loperamide also interferes with the hum an cho linergic system to attenuate pancreaticobiliary secretion.
The results of the present study may also be explained by an increased outflow resistance at the level of the sphincter of Oddi.51,52 However, this is unlikely because basal amylase output was not inhibited, and amino acid-stim ulated amy lase and bilirubin output were not abolished.
A diminished gallbladder motility causes bile stasis, which is a major factor contributing to the formation of gallstones.6'10 Therefore, it may be speculated that patients undergoing long-term treatment with loperamide are at risk for the devel opm ent of gallstone disease. The finding that loperamide also increased the cholesterol saturation index of bile in normal volunteers who took loperamide capsules sufficient to cause E to symptomatic constipation and slowing down of small intesti nal transit supports this notion,53 However, we are not aware of any study dealing with the incidence of gallstone disease in patients undergoing long-term treatm ent with loperamide.
The finding that the short-term adm inistration of lopera mide impairs pancreatic enzyme secretion in healthy subjects may also have clinical implication. As far as we know, there is one study in hum ans that showed an inhibition of pancreatic enzyme secretion by loperamide in patients w ith a short bowel syndrome.38 Although loperamide is generally consid ered a safe drug, w ith few adverse reactions reported w orld wide,54,55 further studies are needed to determ ine the clinical relevance of the inhibitory effects of loperamide on gallblad der motility and pancreatic enzyme secretion, particularly in patients undergoing long-term treatm ent w ith higher doses.
In conclusion, loperamide inhibits basal and amino acidstimulated gallbladder motility and pancreatic enzyme secre tion in humans, despite an enhanced amino acid-stimulated CCK release.
